BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

791 related articles for article (PubMed ID: 27892978)

  • 1. Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA).
    Sperduto PW; Yang TJ; Beal K; Pan H; Brown PD; Bangdiwala A; Shanley R; Yeh N; Gaspar LE; Braunstein S; Sneed P; Boyle J; Kirkpatrick JP; Mak KS; Shih HA; Engelman A; Roberge D; Arvold ND; Alexander B; Awad MM; Contessa J; Chiang V; Hardie J; Ma D; Lou E; Sperduto W; Mehta MP
    JAMA Oncol; 2017 Jun; 3(6):827-831. PubMed ID: 27892978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors.
    Sperduto PW; De B; Li J; Carpenter D; Kirkpatrick J; Milligan M; Shih HA; Kutuk T; Kotecha R; Higaki H; Otsuka M; Aoyama H; Bourgoin M; Roberge D; Dajani S; Sachdev S; Gainey J; Buatti JM; Breen W; Brown PD; Ni L; Braunstein S; Gallitto M; Wang TJC; Shanley R; Lou E; Shiao J; Gaspar LE; Tanabe S; Nakano T; An Y; Chiang V; Zeng L; Soliman H; Elhalawani H; Cagney D; Thomas E; Boggs DH; Ahluwalia MS; Mehta MP
    Int J Radiat Oncol Biol Phys; 2022 Sep; 114(1):60-74. PubMed ID: 35331827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applicability of the adjusted graded prognostic assessment for lung cancer with brain metastases using molecular markers (Lung-molGPA) in a Chinese cohort: A retrospective study of multiple institutions.
    Zhang T; Zhang Y; Zhou L; Deng S; Huang M; Liu Y; Liu Y; Gong Y; Zhu J; Xue J; Bai Y; Ma H; Zhang Y; Yu M; Li Y; Wang Y; Zou B; Zhou X; Xiu W; Na F; Xu Y; Peng F; Wang J; Lu Y
    Cancer Med; 2020 Dec; 9(23):8772-8781. PubMed ID: 33027555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA).
    Sperduto PW; Jiang W; Brown PD; Braunstein S; Sneed P; Wattson DA; Shih HA; Bangdiwala A; Shanley R; Lockney NA; Beal K; Lou E; Amatruda T; Sperduto WA; Kirkpatrick JP; Yeh N; Gaspar LE; Molitoris JK; Masucci L; Roberge D; Yu J; Chiang V; Mehta M
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):812-816. PubMed ID: 29063850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applicability of the lung-molGPA index in non-small cell lung cancer patients with different gene alterations and brain metastases.
    Chen K; Yu X; Zhang F; Xu Y; Zhang P; Huang Z; Fan Y
    Lung Cancer; 2018 Nov; 125():8-13. PubMed ID: 30429042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Therapies and Utility of the Lung-molGPA in Non-Small-Cell Lung Cancer Patients with Brain Metastases.
    Cacho-Díaz B; Cuapantécatl LD; Garcilazo-Reyes YJ; Cabrera-Miranda L; Hernandez-Martinez JM; Arrieta O
    Oncology; 2022; 100(10):542-554. PubMed ID: 35988535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of the graded prognostic assessment for lung cancer with brain metastases using molecular markers (lung-molGPA).
    Nieder C; Hintz M; Oehlke O; Bilger A; Grosu AL
    Radiat Oncol; 2017 Jun; 12(1):107. PubMed ID: 28651600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases.
    Yin K; Li YS; Zheng MM; Jiang BY; Li WF; Yang JJ; Tu HY; Zhou Q; Zhong WZ; Yang XN; Chen HJ; Yan HH; Li LL; Wu YL; Zhang XC
    Lung Cancer; 2019 May; 131():134-138. PubMed ID: 31027690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool.
    Sperduto PW; Deegan BJ; Li J; Jethwa KR; Brown PD; Lockney N; Beal K; Rana NG; Attia A; Tseng CL; Sahgal A; Shanley R; Sperduto WA; Lou E; Zahra A; Buatti JM; Yu JB; Chiang V; Molitoris JK; Masucci L; Roberge D; Shi DD; Shih HA; Olson A; Kirkpatrick JP; Braunstein S; Sneed P; Mehta MP
    Neuro Oncol; 2018 Nov; 20(12):1652-1660. PubMed ID: 30418657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applicability of graded prognostic assessment of lung cancer using molecular markers to lung adenocarcinoma patients with brain metastases.
    Li H; Lian J; Han S; Wang W; Jia H; Cao J; Zhang X; Song X; Jia S; Ren J; Yang W; Xi Y; Lan S
    Oncotarget; 2017 Sep; 8(41):70727-70735. PubMed ID: 29050314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of the Disease-Specific GPA for Patients With 1 to 3 Synchronous Brain Metastases in Newly Diagnosed NSCLC.
    Woody NM; Greer MD; Reddy CA; Videtic GMM; Chao ST; Murphy ES; Suh JH; Angelov L; Barnett GH; Vogelbaum MA; Stephans KL
    Clin Lung Cancer; 2018 Jan; 19(1):e141-e147. PubMed ID: 28739316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain metastases in Japanese NSCLC patients: prognostic assessment and the use of osimertinib and immune checkpoint inhibitors-retrospective study.
    Higaki H; Nishioka K; Otsuka M; Nishikawa N; Shido M; Minatogawa H; Nishikawa Y; Takashina R; Hashimoto T; Katoh N; Taguchi H; Kinoshita R; Yasuda K; Mori T; Uchinami Y; Koizumi F; Fujita Y; Takahashi S; Hattori T; Nishiyama N; Aoyama H
    Radiat Oncol; 2023 Feb; 18(1):25. PubMed ID: 36750899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients.
    Sperduto PW; Chao ST; Sneed PK; Luo X; Suh J; Roberge D; Bhatt A; Jensen AW; Brown PD; Shih H; Kirkpatrick J; Schwer A; Gaspar LE; Fiveash JB; Chiang V; Knisely J; Sperduto CM; Mehta M
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):655-61. PubMed ID: 19942357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of prognostic scores of brain metastases from lung adenocarcinoma with EGFR mutations.
    Li H; Lian J; Jin H; Wang W; Cao J; Zhang X; Song X; Jia S; Jia H; Ren J; Han S; Yang W; Xi Y; Lan S
    J Neurooncol; 2017 May; 133(1):129-135. PubMed ID: 28391386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases.
    Singh C; Qian JM; Yu JB; Chiang VL
    J Neurosurg; 2019 Feb; 132(2):512-517. PubMed ID: 30771783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic Radiosurgery With or Without Whole-Brain Radiotherapy for Brain Metastases: Secondary Analysis of the JROSG 99-1 Randomized Clinical Trial.
    Aoyama H; Tago M; Shirato H;
    JAMA Oncol; 2015 Jul; 1(4):457-64. PubMed ID: 26181254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer.
    Kaul D; Angelidis A; Budach V; Ghadjar P; Kufeld M; Badakhshi H
    Radiat Oncol; 2015 Nov; 10():244. PubMed ID: 26611493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today.
    Sperduto PW; Mesko S; Li J; Cagney D; Aizer A; Lin NU; Nesbit E; Kruser TJ; Chan J; Braunstein S; Lee J; Kirkpatrick JP; Breen W; Brown PD; Shi D; Shih HA; Soliman H; Sahgal A; Shanley R; Sperduto W; Lou E; Everett A; Boggs DH; Masucci L; Roberge D; Remick J; Plichta K; Buatti JM; Jain S; Gaspar LE; Wu CC; Wang TJC; Bryant J; Chuong M; Yu J; Chiang V; Nakano T; Aoyama H; Mehta MP
    Int J Radiat Oncol Biol Phys; 2020 Jun; 107(2):334-343. PubMed ID: 32084525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for Limited Brain Metastases: A Secondary Analysis of the North Central Cancer Treatment Group N0574 (Alliance) Randomized Controlled Trial.
    Churilla TM; Ballman KV; Brown PD; Twohy EL; Jaeckle K; Farace E; Cerhan JH; Anderson SK; Carrero XW; Garces YI; Barker FG; Deming R; Dixon JG; Burri SH; Chung C; Ménard C; Stieber VW; Pollock BE; Galanis E; Buckner JC; Asher AL
    Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1173-1178. PubMed ID: 28939223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status.
    Arrieta O; Ramírez-Tirado LA; Caballé-Perez E; Mejia-Perez A; Zatarain-Barrón ZL; Cardona AF; Lozano-Ruíz F; Segura-González M; Cruz-Rico G; Maldonado F; Rosell R
    Thorac Cancer; 2020 Apr; 11(4):1026-1037. PubMed ID: 32072746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.